Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non-refractory multiple myeloma patients

Isatuximab, carfilzomib, lenalidomide and dexamethasone for high risk MM

Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma

Latest updates in exon 20 insertions focusing on targeted therapies, novel approaches, and implications for patients

Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hodgkin’s lymphoma

Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma

Medical and scientific days of The Institute of Oncology Bucharest 2021 : Steps to the Oncology of Tomorrow

First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukaemia

Breast cancer roundup from ASCO 2021

Phase II study of blinatumomab for MRD-positive B-cell acute lymphoblastic leukaemia

EHA 2021: Latest in immunotherapy for R/R multiple myeloma

OncoAlert and ecancer ASCO roundup - Day 4 and 5